

ASSIGNMENT

WHEREAS, Aya Kikuchi of Tokyo, Japan and Taisuke Nakazawa of Tokyo, Japan; hereinafter collectively called the “Assignor,” has made the invention described in the United States patent application entitled **COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND IMMUNE CHECKPOINT INHIBITORS** that has a U.S. Patent Application Serial Number of 63/387,403, which was filed on December 14, 2022 (hereinafter referred to as “the Application”).

WHEREAS, **Astellas Pharma Europe B.V.**, a Dutch corporation with a principal place of business at Sylviusweg 62, 2333 BE Leiden, The Netherlands; hereinafter called the “Assignee,” desires to acquire the entire right, title and interest in and to the invention and to the Application, and all patents, foreign and domestic, which may be obtained for said invention, as set forth below.

NOW, THEREFORE, in exchange for valuable and legally sufficient consideration, the Assignor has sold, assigned and transferred, and by these presents does sell, assign and transfer to the Assignee, the entire right, title and interest for the United States and elsewhere in and to the invention and the Application; together with the entire right, title and interest in and to all subsequent applications thereof, including, but not limited to, all non-provisional, international, continuation, divisional, or substitute applications thereof, including, for any such subsequent application, the full right to claim the benefit of priority of the Application under any applicable domestic law, international agreement or convention including without limitation the Paris Convention; together with any patents, utility models, inventors’ certificates, and designs that may issue for said invention and applications in the United States and all countries foreign to the United States and all extensions, renewals, and reissues thereof, including without limitation all claims for damages by reason of present, past and future infringement or violation of the foregoing, to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

The Assignor hereby covenants and agrees, for both the Assignor and the Assignor’s legal representative, that Assignor has the full right to convey the interest assigned by this Assignment; and that the Assignor will assist the Assignee in the prosecution of the patent applications identified above, in the making and prosecution of any other applications that the Assignee may elect to make covering the invention identified above, in vesting in the Assignee like exclusive title in and to all such other patent applications and patents, in the prosecution of any patent office proceeding which may arise involving said invention, or any such patent application or patent, and in assisting Assignee in enforcement of any rights arising out of this Assignment; and that the Assignor will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignees to carry out the terms of this Agreement.

The Commissioner for Patents of the United States and the empowered officials of all other governments are hereby authorized and requested to issue patents to the Assignee in accordance with the terms of this Assignment.

IN TESTIMONY WHEREOF, the Assignor has executed this agreement.

Aya Kikuchi
Aya Kikuchi

July, 18, 2023
Date

IN TESTIMONY WHEREOF, the Assignor has executed this agreement.

Taisuke Nakazawa

Taisuke Nakazawa

July 18, 2023

Date

ASSIGNMENT

WHEREAS, Matthew Bernett, Alex Nisthal and Gregory Moore; hereinafter collectively called the "Assignor," has made the invention described in the United States patent application entitled **COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND IMMUNE CHECKPOINT INHIBITORS** that has a U.S. Patent Application Serial Number of 63/387,403, which was filed on December 14, 2022 (hereinafter referred to as "the Application").

WHEREAS, **Xencor, Inc.**, whose office is at 465 North Halstead Street, Suite 200, Pasadena, California 91107, United States of America; hereinafter called the "Assignee," desires to acquire the entire right, title and interest in and to the invention and to the Application, and all patents, foreign and domestic, which may be obtained for said invention, as set forth below.

NOW, THEREFORE, in exchange for valuable and legally sufficient consideration, the Assignor has sold, assigned and transferred, and by these presents does sell, assign and transfer to the Assignee, the entire right, title and interest for the United States and elsewhere in and to the invention and the Application; together with the entire right, title and interest in and to all subsequent applications thereof, including, but not limited to, all non-provisional, international, continuation, divisional, or substitute applications thereof, including, for any such subsequent application, the full right to claim the benefit of priority of the Application under any applicable domestic law, international agreement or convention including without limitation the Paris Convention; together with any patents, utility models, inventors' certificates, and designs that may issue for said invention and applications in the United States and all countries foreign to the United States and all extensions, renewals, and reissues thereof, including without limitation all claims for damages by reason of present, past and future infringement or violation of the foregoing, to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

The Assignor hereby covenants and agrees, for both the Assignor and the Assignor's legal representative, that Assignor has the full right to convey the interest assigned by this Assignment; and that the Assignor will assist the Assignee in the prosecution of the patent applications identified above, in the making and prosecution of any other applications that the Assignee may elect to make covering the invention identified above, in vesting in the Assignee like exclusive title in and to all such other patent applications and patents, in the prosecution of any patent office proceeding which may arise involving said invention, or any such patent application or patent, and in assisting Assignee in enforcement of any rights arising out of this Assignment; and that the Assignor will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignees to carry out the terms of this Agreement.


The Commissioner for Patents of the United States and the empowered officials of all other governments are hereby authorized and requested to issue patents to the Assignee in accordance with the terms of this Assignment.

IN TESTIMONY WHEREOF, the Assignor has executed this agreement.

Matthew J. Bennett
Matthew Bennett


8/30/2023
Date

IN TESTIMONY WHEREOF, the Assignor has executed this agreement.


Alex Nisthal 

8/30/23
Date

IN TESTIMONY WHEREOF, the Assignor has executed this agreement.



Gregory Moore



Date

PATENT ASSIGNMENT AGREEMENT

This PATENT ASSIGNMENT AGREEMENT (the "Agreement") is entered into as of this 4th day of April, 2023, by and between Xencor, Inc., a Delaware corporation with a principal place of business at 465 North Halstead Street, Suite 200, Pasadena, California, 91107 United States of America ("Assignor") and Astellas Pharma Europe B.V., a Dutch corporation with a principal place of business at Sylviusweg 62, 2333 BE Leiden, The Netherlands ("Assignee").

WHEREAS, Assignee has agreed to accept and assume from Assignor all right, title and interest in and to Assignor's Assigned Patent Rights (defined below) and Assignor desires to assign the same to Assignee.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

Assignor hereby assigns, transfers, and conveys to Assignee, and Assignee accepts, all of Assignor's right, title, and interest throughout the world in and to the patents and patent applications set forth on Schedule 1 attached hereto, together with all divisions, continuations, or continuations-in-part thereof, and all patents issuing thereon including reissues, renewals, substitutions, re-examinations and extensions thereof, and any and all corresponding foreign patents and patent applications (collectively, the "Assigned Patent Rights"); and all rights and privileges pertaining to the subject matter above, including, without limitation, all causes of action, claims, demands presently or hereafter accruing with respect to the same, including the right to sue or bring other actions for past, present and future infringement thereof anywhere in the world. Assignor further assigns all rights, and empowers Assignee, its successors, assigns and nominees, to make applications for patent registration or other intellectual property protection anywhere in the world, to claim and receive the benefit of any applicable rights of priority in connection with such applications, to prosecute such applications to issue, and to have any and all registrations issued in the name of Assignee for all Assigned Patent Rights.

Assignor further agrees that Assignor will: (i) cooperate with Assignee in the filing and prosecution of any and all patent registrations or applications or other intellectual property registration or application pertaining to the Assigned Patent Rights; (ii) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer; and (iii) perform such other acts as Assignee lawfully may request, to facilitate Assignee's right to obtain, protect, maintain, defend or enforce any of the Assigned Patent Rights granted hereunder. In the event that Assignee is unable for any reason whatsoever to secure Assignor's signature to any document when so required to effectuate fully this Agreement, Assignor hereby irrevocably designates and appoints Assignee and Assignee's duly authorized officers and agents, as Assignor's agents and attorneys-in-fact to act for and on its behalf and instead of it, to execute and file any such document and to do all other lawfully permitted acts to further the purposes of the foregoing, with the same legal force and effect as if executed by Assignor (it being acknowledged that such appointment a power coupled with an interest).

All aspects of this Agreement, including construction, validity and performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of California. Any disputes between Assignee and Assignor arising out of this Agreement shall be subject to the exclusive jurisdiction of the state and federal courts located in the State of California. The parties hereby consent to and agree to submit to the jurisdiction of such courts. Each of the parties hereto waives, and agrees not to assert in any such dispute, to the fullest extent permitted by applicable law, any claim that: (i) such party is not personally subject to the jurisdiction of such courts, (ii) such party and such party's property is immune from any legal process issued by such courts or (iii) any litigation commenced in such courts is brought in an inconvenient forum.

This Agreement may be executed in counterparts, each of which is deemed an original, but all of which together are deemed to be one and the same agreement.

[Signature Page Follows]

IN WITNESS WHEREOF, intending to be legally bound hereby Assignor has caused this instrument to be signed in its name by its duly authorized representatives as of this 4th day of April 2023.


XENCOR, INC.

By: 

Name: Celia Eckert

Title: Senior Vice President, General Counsel &
Corporate Secretary

Witnessed by: Veronica Flesch

(signature) 
Print Name: Veronica Flesch

(signature) 
Print Name: Eric Chang

IN WITNESS WHEREOF, Assignee has signed his/her name on the dates indicated.

ASTELLAS PHARMA EUROPE B.V.

By: 

Name: Ulrike Schmid

Title: Managing Director

By: 

Name: Stef Schutte

Title: Managing Director

Schedule 1

Assigned Patent Rights

Title	Application No. [Publication No.]	Application Date	Country
COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND IMMUNE CHECKPOINT INHIBITORS	63/387,403	14-Dec-2022	United States of America